Patents Examined by John Doll
  • Patent number: 5310448
    Abstract: A new compositional relationship in the starting charge of a crystal growth station (FIG. 1 ) provides homogeneous monocrystalline lithium niobate. A new measurement system (FIG. 2 ) provides Curie point values of significantly greater accuracy then that of conventional measurements. Careful control of the starting charge composition for crystal growth and effective utilization of the measurement system enable the determination of the compositional range of starting charges for producing congruent crystalline production. The composition corresponds to a mol percentage of 48.35.+-..01 to 48.40.+-..01 of Li.sub.2 O and the remainder Nb2.sub.O 5 for producing homogeneous crystal whose solidification fraction of the molten charge exceeds that which was heretofore achievable.
    Type: Grant
    Filed: August 26, 1988
    Date of Patent: May 10, 1994
    Assignee: Crystal Technology, Inc.
    Inventors: Peter F. Bordui, Richard G. Norwood, John L. Nightingale
  • Patent number: 5185254
    Abstract: A tumor-associated antigen, GA733-1, has been discovered which shares sequence homology with both thyroglobulin type I and interleukin-2 receptors. The antigen is highly expressed in pancreatic carcinoma cells. The antigen is similar to a previously described tumor-associated antigen found in colorectal carcinoma cells. The gene for the antigen is fully sequenced and described here.
    Type: Grant
    Filed: December 29, 1988
    Date of Patent: February 9, 1993
    Assignee: The Wistar Institute
    Inventor: Alban Linnenbach
  • Patent number: 5182368
    Abstract: A new B-cell receptor, Bp50, a 50 kilodalton polypeptide, that functions in B-cell proliferation is described. Ligands such as lymphokines, antibody molecules or the Fv fragments of antibody molecules that bind to Bp50 and augment the proliferation of activated B-cells can be used to regulate B-cell proliferation or differentiation.
    Type: Grant
    Filed: May 24, 1991
    Date of Patent: January 26, 1993
    Inventors: Jeffrey A. Ledbetter, Edward A. Clark
  • Patent number: 5179001
    Abstract: The present invention provides novel compositions and methods useful in the diagnosis and monitoring of Gram-negative infection, especially chronic Pseudomonas aeruginosa infection associated with cystic fibrosis. Pseudomonas aeruginosa strain PAC 605 core lipopolysaccharide determinants are employed as a solid phase antigen in enzyme linked immunosorbant assays and Western blot immunoassay to measure human IgG response to P. aeruginosa infection. The novel compositions are provided in kit form for use in assay methods according to the present invention.
    Type: Grant
    Filed: September 12, 1990
    Date of Patent: January 12, 1993
    Assignee: The Regents of the University of California
    Inventors: Lowell S. Young, Mark A. Jacobson
  • Patent number: 5179018
    Abstract: Mammalian monoclonal anti-lipopolysaccharide (LPS) antibodies which react with gram-negative bacteria across different genera are disclosed. The anti-LPS antibodies are useful for the treatment or prevention of gram-negative bacteremia and for the detection of gram-negative microorganisms.
    Type: Grant
    Filed: October 14, 1983
    Date of Patent: January 12, 1993
    Assignee: Centocor, Inc.
    Inventors: Warren C. Bogard, Jr., Patrick C. Kung
  • Patent number: 5169775
    Abstract: The present invention is directed to monoclonal antibodies, and hybridomas which produce them, which are preferentially reactive with canine lymphoma cells and insignificantly reactive with normal canine lymphocytes.
    Type: Grant
    Filed: June 29, 1990
    Date of Patent: December 8, 1992
    Assignee: The Wistar Institute
    Inventors: Zenon Steplewski, K. Ann Jeglum
  • Patent number: 5166187
    Abstract: This biomaterial comprises at least a compound consisting of an association of collagen, chitosan acetylated to a degree of acetylation between about 10 and about 40% and of glycosaminoglycans.It has its application in orthopedics and plastic surgery and for making extracellular matrices for regeneration of nerve cells and bones as well as biocompatible envelopes.A particular application is the making of artificial skin consisting of a dermal layer of the velvet type obtained from biomaterials such as those described above.The process of obtaining this dermal layer consists in adding a collagen solution of the chitosan, then in adding to the collagen-chitosan a mixture of chondroitins 4- and 6-sulfate.
    Type: Grant
    Filed: February 15, 1989
    Date of Patent: November 24, 1992
    Assignee: Centre National de la Recherche
    Inventors: Christian Collombel, Odile Damour, Christian Gagnieu, Frederique Poinsignon, Christian Echinard, Jacques Marichy
  • Patent number: 5162504
    Abstract: Monoclonal antibodies to prostatic cells, are produced by a hybridoma formed by fusing mouse lymphocytes and mouse myeloma cells. The monoclonal antibodies show specificity for a non-soluble, membrane associated, organ specific antigenic determinant limited in its distribution to normal and neoplastic, human prostate epithelial cells. The monoclonal antibodies, specifically 7E11-C5 monoclonal antibodies, may be suitable for diagnostic uses.
    Type: Grant
    Filed: June 3, 1988
    Date of Patent: November 10, 1992
    Assignee: Cytogen Corporation
    Inventor: Julius S. Horoszewicz
  • Patent number: 5159059
    Abstract: Process for producing a compound of the formula ##STR1## by selectively reducing a compound of the formula ##STR2## in a strong acid medium with excess molar equivalent of reducing agent so that the OH adjacent to X.sub.1 is reduced to H and if Q is OH in the starting material, it optionally may be reduced H.
    Type: Grant
    Filed: May 29, 1990
    Date of Patent: October 27, 1992
    Assignee: Merck & Co., Inc.
    Inventors: James M. Balkovec, Regina C. Black
  • Patent number: 5156841
    Abstract: An antitumor vaccine utilizing oncoproteins as immunogen is disclosed. The oncoprotein could be administered either as isolated, substantially pure product or expressed through a recombinant vaccinia virus containing either the complete coding sequence for the oncoprotein(s) or portions thereof.
    Type: Grant
    Filed: August 26, 1988
    Date of Patent: October 20, 1992
    Assignee: United States of America
    Inventor: Ulf R. Rapp
  • Patent number: 5145770
    Abstract: Disclosed is a method of cryopreserving a sheet of living, cultured epithelial cells for use as a skin wound dressing. The method ensures that the integrity of the sheet will be maintained, and it preserves a significant number of cells in a mitotically competent, physiologically healthy form. It involves use of a non cell penetrating cryoprotectant and certain freezing and thawing conditions.
    Type: Grant
    Filed: June 4, 1990
    Date of Patent: September 8, 1992
    Assignee: BioSurface Technology, Inc.
    Inventors: Ross A. Tubo, Susan F. Schaeffer, Alexander Schermer, Richard Odessey
  • Patent number: 5143842
    Abstract: An improved basal nutrient medium MCDB 120 for the clonal growth of human muscle satellite cells (HMSC) is described. In addition, a serum-free supplement for the clonal growth of HMSC containing serum albumin, dexamethasone, fetuin epidermal growth factor and insulin. Combination of MCDB 120 and the serum-free supplement results in a serum-free medium for growth of HMSC. The serum-free supplement can also be used with other basal nutrient media such as MCDB 131M for growth of HMSC. Addition of 5% dialyzed fetal bovine serum to the serum-free media described results in semi-defined media which allows significantly improved growth of HMSC.
    Type: Grant
    Filed: November 1, 1988
    Date of Patent: September 1, 1992
    Assignee: The University of Colorado Foundation, Inc.
    Inventors: Richard G. Ham, Judith A. St. Clair
  • Patent number: 5143843
    Abstract: Monoclonal antibodies to human antigens present on a majority of human cells are described. These mAbs have use in a method for isolating mAb for less expressive antigens, such as cancer antigens, or other antigens associated with particular abnormalities, disorders or disease state. The latter mAbs may be weaker than or not present to such an extent as the first mentioned mAbs. For example, these less expressive mAbs would be useful for cancer diagnosis, especially in the early stages, and for cancer treatment as well where the cancer cell is the target cell for the mAb. The mAb can be tagged with a tissue destructive agent such as a radio-label, a toxin, a chemical poisen, and the like. Some of the mAbs described, subset tumors of particular types and so are useful for tumor subclassification. The mAbs described are also useful in analyzing the properties and functions of their respective antigens in human cells.
    Type: Grant
    Filed: July 18, 1991
    Date of Patent: September 1, 1992
    Assignee: Sloan-Kettering Institute For Cancer Research
    Inventors: M. Jules Mattes, Lloyd J. Old, Kenneth O. Lloyd
  • Patent number: 5144010
    Abstract: This invention provides an auto-anti-idiotypic method for producing a monoclonal anti-idiotypic antibody. The method involves contacting lymphoid cells of an animal under suitable conditions with an effective antibody-raising amount of an antigen, collecting the lymphoid cells from the animal at a suitable time after the contacting and fusing the collected lymphoid cells with appropriate myeloma cells to produce a series of hybridoma cells each of which produces a monoclonal antibody. The method further involves screening, under suitable conditions, the series of hybridoma cells so produced to identify those which secrete a monoclonal antibody capable of binding to an antibody directed to the antigen, or to a receptor where the antigen is a ligand to the receptor, separately culturing a hybridoma cell so identified in an appropriate medium, and separately recovering under suitable conditions the monoclonal anti-idiotypic antibody produced by the hybridoma cell.
    Type: Grant
    Filed: November 18, 1989
    Date of Patent: September 1, 1992
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Bernard F. Erlanger, William L. Cleveland
  • Patent number: 5141865
    Abstract: Monoclonal antibodies which bind thromboxane A2 receptor antagonists, hybrid cell lines which produce these monoclonal antibodies, and immunoassay methods for detecting thromboxane A2 receptor antagonists using these monoclonal antibodies.
    Type: Grant
    Filed: November 17, 1989
    Date of Patent: August 25, 1992
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Edward M. Croze, Jan-I Tu
  • Patent number: 5141864
    Abstract: A hybridoma capable of producing a monoclonal antibody specific to a sialic acid containing glycolipid carrying N-acetylneuraminic acid residue having alpha 2.fwdarw.3 linkage is herein disclosed. The hybridoma can be generated by fusing (i) B cells or lymphocytes obtained by immunizing an animal with a sialic acid containing glycolipid carrying N-acetylneuraminic acid residue having alpha 2.fwdarw.3 linkage and (ii) myeloma cells. The monoclonal antibody produced by the hybridoma can be used for purifying gangliosides, for treating patients suffering from melanoma and for diagnosing sera.
    Type: Grant
    Filed: November 14, 1988
    Date of Patent: August 25, 1992
    Assignee: Mect Corporation
    Inventors: Yoshitaka Nagai, Hideki Yamamoto, Kinji Takada, Ito, Yoshiyasu Shitori
  • Patent number: 5138793
    Abstract: Plant embryos are preserved by coating a plant embryo with oil in an amount sufficient for causing hypoxia and then cooling and storing the coated embryo at a temperature above the cold sensitivity threshold of the embryo.
    Type: Grant
    Filed: June 25, 1990
    Date of Patent: August 18, 1992
    Assignee: Nestec S.A.
    Inventors: Bruno Florin, Vincent Petiard
  • Patent number: 5134065
    Abstract: A novel and unique plasminogen activator inhibitor fragment is obtained from human umbilical vein endothelial cells which has the following characteristics:A. it is derived from a native t-PA inhibitor that binds to and inhibits the activity of t-PA,B. it is dissociated from a complex formed between said native t-PA inhibitor and t-PA, said complex existing in two distinct interconvertible conformations with molecular weight of about 88 KDa and 105 KDa, respectively, and being partially reversible in the presence of fibrin,C. it has a molecular weight of about 40 KDa when dissociated from the complex, andD. it has a novel partial N-terminal amino acid sequence when dissociated from the complex.
    Type: Grant
    Filed: May 16, 1986
    Date of Patent: July 28, 1992
    Assignee: Monsanto Company
    Inventors: Michael A. Sanzo, Arthur J. Wittwer, Jayne C. Marasa, Joseph Feder
  • Patent number: 5132405
    Abstract: Disclosed are a family of synthetic proteins having affinity for a preselected antigen. The proteins are characterized by one or more sequencesThe United States government has rights in this invention pursuant to small business innovation research grant number SSS-4 1 R43 CA39870-01 and SSS-4 2 R44 CA39870-02. This application is a continuation of copending application Ser. No. 052,800 filed May 21, 1987.
    Type: Grant
    Filed: June 30, 1988
    Date of Patent: July 21, 1992
    Assignee: Creative BioMolecules, Inc.
    Inventors: James S. Huston, Hermann Oppermann
  • Patent number: 5132214
    Abstract: Plasminogen activators (PA) are obtained from cultured normal human colon cells which are adaptable to large scale production. A purified tissue PA (t-PA) is obtained from CCD-18Co normal human colon fibroblast cells which shows chemical differences from Bowes melanoma t-PA.
    Type: Grant
    Filed: April 9, 1986
    Date of Patent: July 21, 1992
    Assignee: Monsanto Company
    Inventors: Joseph Feder, Nicholaos K. Harakas, Jon P. Schaumann, Daniel T. Connolly, Arthur J. Wittwer